Anti-wrinkle treatments
Lower-face anti-wrinkle treatment: why the number of areas is not a treatment plan
Lower-face muscles work together during smiling, speaking and eating. New evidence shows why treatment extent, anatomy and function matter more than choosing a package by its number of areas.
The lower face is a moving system
The muscles around the mouth, jawline and neck do not work as isolated cosmetic zones. They balance one another during smiling, speaking, drinking and eating. A small change in one muscle may alter the way a neighbouring muscle pulls, so a diagram or an ‘area’ selected from a price list cannot replace examination.
The starting concern also needs definition. A downturned mouth corner, chin texture, lower-lip asymmetry, jaw width and neck bands arise from different structures and movements. Skin laxity, volume loss, dental support and bone shape may contribute but will not be corrected by reducing muscle activity.
What did the new lower-face trial test?
A 2026 randomised, double-blind trial allocated 80 participants to four lower-face treatment plans that differed in the number and distribution of injection points across selected downward-pulling muscles. Researchers used three-dimensional photography, clinician assessments and patient-reported questionnaires at 15, 30 and 90 days.
Broader treatment produced greater measured tissue displacement at day 15 and the effect persisted more strongly in the intermediate-to-high coverage groups. However, the most extensive group reported more adverse effects at day 90. This supports a benefit-risk discussion rather than the assumption that treating more points must be better.
Why the findings still need restraint
The study measured displacement and satisfaction over only three months. It does not show that the broadest plan suits every face, produces a more natural expression or provides the best balance between appearance and function. A measurable lift may be too subtle, unnecessary or unwanted for an individual patient.
Another 2026 prospective study compared injection positions for a mouth-corner muscle and then examined the addition of a neck muscle. It reported small changes in mouth-corner position and no severe adverse events, but part of the study was non-randomised and it came from one centre. Its mapping should not be copied without individual assessment.
An ‘area’ does not describe a prescription
Two people asking about the same lower-face area may need different advice—or no treatment. Baseline smile pattern, existing asymmetry, muscle strength, facial proportions, previous response and the importance of preserving a particular expression all affect the plan. Dose, depth and exact placement also matter; an area count describes none of these.
A consultation should examine the face at rest and during several expressions, clarify the change the patient wants and explain which concerns are unlikely to respond. Standardised photographs can document the starting point. If the likely benefit is small or the functional trade-off is unacceptable, declining treatment is a valid outcome.
Downtime and possible adverse effects
Short-term effects may include redness, tenderness, swelling, pinpoint marks or bruising. Unwanted local effects can include a changed smile, lower-lip weakness, increased asymmetry or difficulty with particular mouth movements. These effects may take time to settle because an injected treatment cannot simply be removed after administration.
The MHRA strengthened UK warnings in July 2026 after rare reports of a serious effect spreading beyond the injection site. Difficulty swallowing, slurred speech, breathing difficulty or generalised muscle weakness can occur days or weeks after treatment and require immediate medical attention. Patients need clear emergency and follow-up instructions before treatment.
Suitability must be assessed in person
Medical history should cover previous swallowing, speech or breathing problems, neurological or muscular conditions, medicines, allergies, pregnancy or breastfeeding, previous injectable reactions and planned dental or facial procedures. Active infection or inflammation near an injection site may mean postponing treatment. Product-specific suitability must be checked by the prescriber.
GMC guidance requires a physical examination before prescribing injectable cosmetic medicines and an honest discussion of evidence, alternatives, risks and follow-up. For the lower face, safe decision-making begins with anatomy and function—not with maximising the number of areas or promising a particular expression.